SEC Form 4 · accession 0000899243-18-001904
Cardiff Oncology, Inc. · CRDF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Erlander
Officer — Chief Scientific Officer
Period of report
Jan 23, 2018
Accepted (ET)
Jan 25, 2018 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001213037
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $0.30 | Jan 23, 2018 | A | 672,189 | A | — | Jan 23, 2028 | Common Stock | 672,189 | 1,782,189 | D |
Explanation of responses
- F1522,189 vest immediately upon grant and 50,000 vest on each of 1/23/2019, 2020 and 2021.